Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Diversity of genetic events associated with MLH1 promoter methylation in Lynch syndrome families with heritable constitutional epimutation.

Leclerc J, Flament C, Lovecchio T, Delattre L, Ait Yahya E, Baert-Desurmont S, Burnichon N, Bronner M, Cabaret O, Lejeune S, Guimbaud R, Morin G, Mauillon J, Jonveaux P, Laurent-Puig P, Frébourg T, Porchet N, Buisine MP.

Genet Med. 2018 Apr 12. doi: 10.1038/gim.2018.47. [Epub ahead of print]

PMID:
29790873
2.

[Psychiatric readmissions: individual and organizational factors].

Plancke L, Amariei A, Flament C, Dumesnil C.

Sante Publique. 2017 Nov-Dec;29(6):829-836. doi: 10.3917/spub.176.0829. French.

PMID:
29473397
3.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
4.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

5.

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.

Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, Duong CPM, Flament C, Lepage P, Roberti MP, Routy B, Jacquelot N, Apetoh L, Becharef S, Rusakiewicz S, Langella P, Sokol H, Kroemer G, Enot D, Roux A, Eggermont A, Tartour E, Johannes L, Woerther PL, Chachaty E, Soria JC, Golden E, Formenti S, Plebanski M, Madondo M, Rosenstiel P, Raoult D, Cattoir V, Boneca IG, Chamaillard M, Zitvogel L.

Immunity. 2016 Oct 18;45(4):931-943. doi: 10.1016/j.immuni.2016.09.009. Epub 2016 Oct 4.

6.

[Chemokine receptors expression on T cells: contribution to diagnosis of melanoma metastasis dissemination status].

Jacquelot N, Enot DP, Flament C, Dalle S, Zitvogel L.

Med Sci (Paris). 2016 8-9;32(8-9):690-2. doi: 10.1051/medsci/20163208010. Epub 2016 Sep 12. French. No abstract available.

7.

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

Jacquelot N, Enot DP, Flament C, Vimond N, Blattner C, Pitt JM, Yamazaki T, Roberti MP, Daillère R, Vétizou M, Poirier-Colame V, Semeraro M, Caignard A, Slingluff CL Jr, Sallusto F, Rusakiewicz S, Weide B, Marabelle A, Kohrt H, Dalle S, Cavalcanti A, Kroemer G, Di Giacomo AM, Maio M, Wong P, Yuan J, Wolchok J, Umansky V, Eggermont A, Zitvogel L.

J Clin Invest. 2016 Mar 1;126(3):921-37. doi: 10.1172/JCI80071. Epub 2016 Feb 8.

8.

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L.

Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.

9.

Pharmacokinetics of paracetamol in Göttingen minipigs: in vivo studies and modeling to elucidate physiological determinants of absorption.

Suenderhauf C, Tuffin G, Lorentsen H, Grimm HP, Flament C, Parrott N.

Pharm Res. 2014 Oct;31(10):2696-707. doi: 10.1007/s11095-014-1367-6. Epub 2014 May 3.

PMID:
24792825
10.

Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab.

Goéré D, Gras-Chaput N, Aupérin A, Flament C, Mariette C, Glehen O, Zitvogel L, Elias D.

BMC Cancer. 2014 Mar 4;14:148. doi: 10.1186/1471-2407-14-148.

11.

Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.

Romero AI, Chaput N, Poirier-Colame V, Rusakiewicz S, Jacquelot N, Chaba K, Mortier E, Jacques Y, Caillat-Zucman S, Flament C, Caignard A, Messaoudene M, Aupérin A, Vielh P, Dessen P, Porta C, Mateus C, Ayyoub M, Valmori D, Eggermont A, Robert C, Zitvogel L.

Cancer Res. 2014 Jan 1;74(1):68-80. doi: 10.1158/0008-5472.CAN-13-1186. Epub 2013 Nov 6.

12.

NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome.

Rusakiewicz S, Nocturne G, Lazure T, Semeraro M, Flament C, Caillat-Zucman S, Sène D, Delahaye N, Vivier E, Chaba K, Poirier-Colame V, Nordmark G, Eloranta ML, Eriksson P, Theander E, Forsblad-d'Elia H, Omdal R, Wahren-Herlenius M, Jonsson R, Rönnblom L, Nititham J, Taylor KE, Lessard CJ, Sivils KL, Gottenberg JE, Criswell LA, Miceli-Richard C, Zitvogel L, Mariette X.

Sci Transl Med. 2013 Jul 24;5(195):195ra96. doi: 10.1126/scitranslmed.3005727.

13.

Potent immunomodulatory effects of the trifunctional antibody catumaxomab.

Goéré D, Flament C, Rusakiewicz S, Poirier-Colame V, Kepp O, Martins I, Pesquet J, Eggermont A, Elias D, Chaput N, Zitvogel L.

Cancer Res. 2013 Aug 1;73(15):4663-73. doi: 10.1158/0008-5472.CAN-12-4460. Epub 2013 Jun 4.

14.

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.

Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, Chaigneau L, Le Brun-Ly V, Dubreuil P, Cremer I, Caignard A, Poirier-Colame V, Chaba K, Flament C, Halama N, Jäger D, Eggermont A, Bonvalot S, Commo F, Terrier P, Opolon P, Emile JF, Coindre JM, Kroemer G, Chaput N, Le Cesne A, Blay JY, Zitvogel L.

Cancer Res. 2013 Jun 15;73(12):3499-510. doi: 10.1158/0008-5472.CAN-13-0371. Epub 2013 Apr 16.

15.

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome.

Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC, Paci A, Rosenzwajg M, Klatzmann D, Eggermont A, Robert C, Zitvogel L.

Oncoimmunology. 2013 Feb 1;2(2):e23080.

16.

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.

Pautier P, Locher C, Robert C, Deroussent A, Flament C, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, Vassal G, Eggermont A, Zitvogel L, Chaput N, Paci A.

Oncoimmunology. 2013 Feb 1;2(2):e23079.

17.

CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.

Lindemann L, Jaeschke G, Michalon A, Vieira E, Honer M, Spooren W, Porter R, Hartung T, Kolczewski S, Büttelmann B, Flament C, Diener C, Fischer C, Gatti S, Prinssen EP, Parrott N, Hoffmann G, Wettstein JG.

J Pharmacol Exp Ther. 2011 Nov;339(2):474-86. doi: 10.1124/jpet.111.185660. Epub 2011 Aug 17.

18.

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors.

Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, Minard-Colin V, Poirier-Colame V, Chaba K, Flament C, Baud V, Authier H, Kerdine-Römer S, Pallardy M, Cremer I, Peaudecerf L, Rocha B, Valteau-Couanet D, Gutierrez JC, Nunès JA, Commo F, Bonvalot S, Ibrahim N, Terrier P, Opolon P, Bottino C, Moretta A, Tavernier J, Rihet P, Coindre JM, Blay JY, Isambert N, Emile JF, Vivier E, Lecesne A, Kroemer G, Zitvogel L.

Nat Med. 2011 Jun;17(6):700-7. doi: 10.1038/nm.2366. Epub 2011 May 8.

PMID:
21552268
19.

An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.

Zoubir M, Flament C, Gdoura A, Bahleda R, Litvinova E, Soumelis V, Conforti R, Viaud S, Soria JC, Kroemer G, Zitvogel L, Chaput N.

Cell Cycle. 2011 Jan 1;10(1):118-26. Epub 2011 Jan 1.

PMID:
21200142
20.

Cyclophosphamide induces differentiation of Th17 cells in cancer patients.

Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, Soria JC, Marty V, Vielh P, Robert C, Chaput N, Zitvogel L.

Cancer Res. 2011 Feb 1;71(3):661-5. doi: 10.1158/0008-5472.CAN-10-1259. Epub 2010 Dec 9.

21.

Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia.

Wemeau M, Kepp O, Tesnière A, Panaretakis T, Flament C, De Botton S, Zitvogel L, Kroemer G, Chaput N.

Cell Death Dis. 2010 Dec 2;1:e104. doi: 10.1038/cddis.2010.82.

22.

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.

Ménard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taïeb J, Delahaye NF, Flament C, Emile JF, Le Cesne A, Zitvogel L.

Cancer Res. 2009 Apr 15;69(8):3563-9. doi: 10.1158/0008-5472.CAN-08-3807. Epub 2009 Apr 7.

23.

Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha.

Viaud S, Terme M, Flament C, Taieb J, André F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T, Zitvogel L, Chaput N.

PLoS One. 2009;4(3):e4942. doi: 10.1371/journal.pone.0004942. Epub 2009 Mar 25.

24.

Dendritic cells and innate defense against tumor cells.

Ullrich E, Ménard C, Flament C, Terme M, Mignot G, Bonmort M, Plumas J, Chaperot L, Chaput N, Zitvogel L.

Cytokine Growth Factor Rev. 2008 Feb;19(1):79-92. Epub 2007 Dec 26. Review.

PMID:
18155952
25.

Ecto-calreticulin in immunogenic chemotherapy.

Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P, Ghiringhelli F, Apetoh L, Chaput N, Flament C, Ullrich E, de Botton S, Zitvogel L, Kroemer G.

Immunol Rev. 2007 Dec;220:22-34. Review.

PMID:
17979837
26.

Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.

Chaput N, De Botton S, Obeid M, Apetoh L, Ghiringhelli F, Panaretakis T, Flament C, Zitvogel L, Kroemer G.

J Mol Med (Berl). 2007 Oct;85(10):1069-76. Epub 2007 May 22. Review.

PMID:
17891368
27.

Dendritic cell derived-exosomes: biology and clinical implementations.

Chaput N, Flament C, Viaud S, Taieb J, Roux S, Spatz A, André F, LePecq JB, Boussac M, Garin J, Amigorena S, Théry C, Zitvogel L.

J Leukoc Biol. 2006 Sep;80(3):471-8. Epub 2006 Jun 29. Review.

PMID:
16809645
28.

A novel dendritic cell subset involved in tumor immunosurveillance.

Taieb J, Chaput N, Ménard C, Apetoh L, Ullrich E, Bonmort M, Péquignot M, Casares N, Terme M, Flament C, Opolon P, Lecluse Y, Métivier D, Tomasello E, Vivier E, Ghiringhelli F, Martin F, Klatzmann D, Poynard T, Tursz T, Raposo G, Yagita H, Ryffel B, Kroemer G, Zitvogel L.

Nat Med. 2006 Feb;12(2):214-9. Epub 2006 Jan 29.

PMID:
16444265
29.

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Lecesne A, Robert C, Blay JY, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchencker W, Martin F, Zitvogel L.

J Exp Med. 2005 Oct 17;202(8):1075-85.

30.

The potential of exosomes in immunotherapy of cancer.

Chaput N, Taïeb J, Schartz N, Flament C, Novault S, André F, Zitvogel L.

Blood Cells Mol Dis. 2005 Sep-Oct;35(2):111-5. Review.

PMID:
16027014
31.

BCR/ABL promotes dendritic cell-mediated natural killer cell activation.

Terme M, Borg C, Guilhot F, Masurier C, Flament C, Wagner EF, Caillat-Zucman S, Bernheim A, Turhan AG, Caignard A, Zitvogel L.

Cancer Res. 2005 Jul 15;65(14):6409-17.

32.

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial.

Escudier B, Dorval T, Chaput N, André F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert C, Serra V, Valente N, Le Pecq JB, Spatz A, Lantz O, Tursz T, Angevin E, Zitvogel L.

J Transl Med. 2005 Mar 2;3(1):10.

33.

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.

Borg C, Terme M, Taïeb J, Ménard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, Le Cesne A, Chung-Scott V, Lazar V, Tchou I, Crépineau F, Lemoine F, Bernard J, Fletcher JA, Turhan A, Blay JY, Spatz A, Emile JF, Heinrich MC, Mécheri S, Tursz T, Zitvogel L.

J Clin Invest. 2004 Aug;114(3):379-88.

34.

IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules.

Terme M, Tomasello E, Maruyama K, Crépineau F, Chaput N, Flament C, Marolleau JP, Angevin E, Wagner EF, Salomon B, Lemonnier FA, Wakasugi H, Colonna M, Vivier E, Zitvogel L.

J Immunol. 2004 May 15;172(10):5957-66.

35.

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.

André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L.

J Immunol. 2004 Feb 15;172(4):2126-36.

36.

[NK cell-based immunotherapy: new prospects and involvement of dendritic cells].

Borg C, Taieb J, Terme M, Maruyama K, Flament C, Angevin E, Zitvogel L.

Bull Cancer. 2003 Aug-Sep;90(8-9):699-705. Review. French.

37.

[Exosomes and anti-tumour immunotherapy].

Chaput N, Andre F, Schartz NE, Flament C, Angevin E, Escudier B, Zitvogel L.

Bull Cancer. 2003 Aug-Sep;90(8-9):695-8. French.

38.

Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats.

Bittner B, González RC, Isel H, Flament C.

Eur J Pharm Biopharm. 2003 Jul;56(1):143-6.

PMID:
12837492
39.

Tumor-derived exosomes: a new source of tumor rejection antigens.

André F, Schartz NE, Chaput N, Flament C, Raposo G, Amigorena S, Angevin E, Zitvogel L.

Vaccine. 2002 Dec 19;20 Suppl 4:A28-31. Review.

PMID:
12477425
40.

Malignant effusions and immunogenic tumour-derived exosomes.

Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L.

Lancet. 2002 Jul 27;360(9329):295-305.

PMID:
12147373
41.

Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk.

Fernandez NC, Flament C, Crépineau F, Angevin E, Vivier E, Zitvogel L.

Eur Cytokine Netw. 2002 Jan-Mar;13(1):17-27.

42.

Exosomes in cancer immunotherapy: preclinical data.

Andre F, Andersen M, Wolfers J, Lozier A, Raposo G, Serra V, Ruegg C, Flament C, Angevin E, Amigorena S, Zitvogel L.

Adv Exp Med Biol. 2001;495:349-54. Review. No abstract available.

PMID:
11774591
43.

Equilibrium states and ground state of two-dimensional fluid foams.

Graner F, Jiang Y, Janiaud E, Flament C.

Phys Rev E Stat Nonlin Soft Matter Phys. 2001 Jan;63(1 Pt 1):011402. Epub 2000 Dec 20.

PMID:
11304255
44.

Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.

Wolfers J, Lozier A, Raposo G, Regnault A, Théry C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S, Zitvogel L.

Nat Med. 2001 Mar;7(3):297-303.

PMID:
11231627
45.

Rayleigh-taylor instability with magnetic fluids: experiment and theory

Pacitto G, Flament C, Bacri JC, Widom M.

Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics. 2000 Dec;62(6 Pt A):7941-8.

PMID:
11138077
46.
47.

Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo.

Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L.

Nat Med. 1999 Apr;5(4):405-11.

PMID:
10202929
48.

Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.

Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S.

Nat Med. 1998 May;4(5):594-600.

PMID:
9585234
49.

Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines.

Dufour E, Carcelain G, Gaudin C, Flament C, Avril MF, Faure F.

J Immunol. 1997 Apr 15;158(8):3787-95.

PMID:
9103444
50.

TCR alpha/beta and TCR gamma/delta CD4-/CD8- HLA-DR alloreactive CTL clones do not use Fas/Fas ligand pathway to lyse their specific target cells.

Mami-Chouaib F, Flament C, Asselin-Paturel C, Gaudin C, Chouaib S.

Hum Immunol. 1996 Nov;51(1):13-22.

PMID:
8911993

Supplemental Content

Loading ...
Support Center